Karen Akinsanya
President, Head of Therapeutics R&D and Chief Strategy Officer & PartnershipsDr. Karen Akinsanya, Ph.D. is Director of Nautilus Biotechnology, Inc. from March 2022. Dr. Akinsanya is Member of Scientific Advisory Board of Thermo Fisher Scientific Inc. Dr. Akinsanya served as President of Research &Development Therapeutics for Schrödinger, Inc. since February 2022 until May 2025 and serves as its President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships since 2025. She served as Executive Vice President, Head of Discovery R&D and Chief Biomedical Scientist at Schrödinger, Inc. since January 2020 until February 2022. She previously served as Senior Vice President for Schrödinger, Inc. from April 2018 to December 2019. Dr. Akinsanya serves as Member of Scientific Advisory Board at Variant Bio Inc. since September 2020. Dr. Akinsanya spent at Merck & Co. Inc. or Merck, a pharmaceutical company, where she held a variety of positions across Merck Research Labs, including associate Vice President, early scientific assessment lead, business development & licensing from December 2013 to July 2017, collaboration lead and Executive Director, cardiovascular research from January 2010 to December 2013 and associate Director, clinical pharmacology from October 2005 to December 2009. Prior to Merck, she held a number of roles in drug discovery at Ferring Pharmaceuticals in the United Kingdom and the United States from 1997 to 2005. In 2007, Dr. Akinsanya founded Envision Science Group LLC, or Envision, a translational science consulting company, where she currently serves as President. Dr. Akinsanya provided consulting services on behalf of Envision to companies in the pharmaceutical industry between July 2017 and April 2018. Dr. Akinsanya received a B.Sc. in Biochemistry from Queen Mary College, University of London, a Ph.D. in Endocrine Physiology from the Imperial College and completed postdoctoral studies at the Ludwig Institute for Cancer Research, University College, London.
Positions
- Company NameSchrödinger, Inc.Stock CodeSDGRPositionPresident, Head of Therapeutics R&D and Chief Strategy Officer & PartnershipsColleagues
- RFRamy FaridCEO, President & Director
- MMMichael M. LyntonIndependent Chairman of the Board
- RARichard A. FriesnerCo-Founder, Scientific Advisory Chairman and Director
- RJRichie JainExecutive VP, CFO & Treasurer
- YTYvonne TranCorporate Secretary, Chief Legal & People Officer
- WGWilliam GoddardCo-Founder & Scientific Advisor
- GLGary L. SenderIndependent Director
